Key facts
- This page summarizes Christopher Heery's Form 4 filing for Arcellx, Inc. (ACLX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 Sep 2024, 17:48.
Christopher Heery - 05 Sep 2024 Form 4 Insider Report for Arcellx, Inc. (ACLX)
- Reporting relationship
- CHIEF MEDICAL OFFICER
- Issuer ticker
- ACLX
- Reported as of
- 05 Sep 2024
- Net transaction value
- -$188,211
- SEC form
- 4
- Accepted by SEC
- 06 Sep 2024, 17:48:11 UTC
- Prior SEC filing
- 03 Sep 2024
- Next SEC filing
- 10 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michelle Gilson, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Heery filed Form 4 for Arcellx, Inc. (ACLX) on 06 Sep 2024.
Change
- Previous filing in this sequence was filed on 03 Sep 2024.
- Current net transaction value: -$188,211.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACLX
transaction
Common Stock
Options Exercise
- Transaction value
- $51,315
- Shares
- +3,421
- Change %
- +37%
- Price
- $15.00
- Shares after
- 12,699
- Date
- 05 Sep 2024
- Ownership
- Direct
ACLX
transaction
Common Stock
Sale
- Transaction value
- $239,526
- Shares
- -3,421
- Change %
- -27%
- Price
- $70.02
- Shares after
- 9,278
- Date
- 05 Sep 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACLX
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -3,421
- Change %
- -2.5%
- Price
- $0.000000
- Shares after
- 132,416
- Date
- 05 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,421
- Exercise price
- $15.00
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 22, 2023.
Footnote F2
Represents the weighted average share price of an aggregate total of 3,421 shares sold in the price range of $70.00 to $70.15 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Footnote F3
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following the Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Equity Grant Date" shall mean February 3, 2022.